HBIO vs ROL · rev $22.7M vs P/E 41, rev $1.99B
Harvard Bioscience Inc (HBIO) versus Rollins Inc (ROL) — a side-by-side from cached financials, not a winner call.
Harvard Bioscience Inc (HBIO) is a medical instruments & supplies company listed on US.
Rollins Inc (ROL) is a personal services company listed on NYSE.
Latest reported HBIO revenue for 2026-06-30 was $22.7M. Net income was -$2.9M. Revenue was up 9.5% from 2026-03-31 to 2026-06-30. HBIO currently screens at market cap $20.3M.
Latest reported ROL revenue for 2026-06-30 was $1.99B. Net income was $251.7M. ROL currently screens at market cap $21.73B and trailing P/E 41.4.
HBIO currently screens at market cap $20.3M. ROL currently screens at market cap $21.73B and trailing P/E 41.4.
Not investment advice. Open the HBIO and ROL stock pages for the full models.
Not investment advice.